Hua Medicine (2552) H1 2025 earnings summary

Executive summary

• Achieved 112% year-over-year revenue growth in H1 2025, reaching RMB 217.4 million, driven by full self-commercialization of HuaTangNing and expanded hospital coverage after regaining rights from Bayer.

• Reported first half-year profit of RMB 1.18 billion, primarily due to a one-time release of RMB 1.24 billion in deferred income from the Bayer agreement termination.

• Gross margin improved to 54.2% from 46.5% year-over-year, with gross profit up 147% to RMB 117.8 million.

• Prescription and patient access expanded, especially in Tier 2 and Tier 3 hospitals, supported by NRDL inclusion.

• Advanced post-marketing and real-world studies, including the 2,000-patient BLOOM study, and filed for dorzagliatin registration in Hong Kong.

Financial highlights

• Revenue for H1 2025: RMB 217.4 million, up 112% year-over-year; sales volume up 108% to 1,764,000 packs.

• Gross profit: RMB 117.8 million, up 147% year-over-year; gross margin: 54.2%.

• Net profit for H1 2025: RMB 1.18 billion, mainly from a one-time release of RMB 1.24 billion in deferred income.

• Cash and cash equivalents: RMB 1,022.8 million as of June 30, 2025.

• Selling expenses as a percentage of revenue dropped significantly, improving operational leverage.

Outlook and guidance

• Confident in achieving or exceeding RMB 1 billion in annual sales by 2027, with continued 30-40% annual revenue growth expected.

• Focus on expanding commercialization, R&D for dorzagliatin and 2nd generation GKA, and new indications in metabolic disorders.

• Plans to increase sales team by 30% and invest in digital platforms and AI for operational efficiency.

• Bioequivalence study for dorzagliatin-metformin fixed dose combination planned for early 2026, with product launch anticipated in 2028-2029.

• R&D spending expected to rise, leveraging stable sales growth.